SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Zcash is a privacy-focused cryptocurrency that uses trustless zero-knowledge proofs to enable fully encrypted transactions while maintaining blockchain transparency and security. It was the first cryptocurrency to implement zero-knowledge encryption for private peer-to-peer payments, addressing the fundamental privacy gap in traditional cryptocurrencies that expose transaction details publicly.   With a fixed supply of 21 million ZEC and a halving schedule similar to Bitcoin, Zcash allows users to prove transactions are valid without revealing sensitive information like wallet balances, transaction amounts, or participant identities, making it suitable for everyday payments, long-term savings, and cross-border money transfers where financial confidentiality matters.  The protocol operates on its own blockchain currently using Proof-of-Work consensus, though it's evolving toward Proof-of-Stake through the planned "Crosslink" upgrade to enhance security, scalability, and energy efficiency. Zcash employs trustless zero-knowledge proofs (Halo) within its Orchard shielded pool to verify transactions without revealing sender, receiver, or amount information.   Users can choose between transparent public transactions and shielded private transactions through Unified Addresses, which work with both types. The network is faster and cheaper than Bitcoin, with new blocks mined every 75 seconds and transaction fees typically just a fraction of a cent. Privacy adoption has surged in 2025, with over 30% of total ZEC supply now held in fully shielded pools.  Zcash was created by a group of scientists in 2013 who initially proposed Zerocoin as a privacy extension to Bitcoin before building a standalone protocol. The ecosystem operates with a self-funded development model where block rewards support independent teams through the Zcash Community Grants Committee and a new Coinholder-Controlled Fund.

Zcash

Zcash is trending as the community discusses its potential as a privacy-focused alternative to Bitcoin, with some suggesting a rotation from BTC into ZEC. Bullish sentiment is fueled by news of increased institutional interest and a company backed by the Winklevoss twins accumulating a significant ZEC treasury, leading to speculation about a possible price surge.

Shiba Inu (SHIB) is a meme token which began as a fun currency and has now transformed into a decentralized ecosystem. During the initial launch, 50% of the supply was allocated into Vitalik Buterin's ethereum wallet.   As a result of that, Vitalik proceeded to donate 10% of his SHIB holdings to a COVID-19 relief effort in India and the remaining 40% is burnt forever. That donation was worth about $1 billion at that time, which makes it one of the largest donation ever in the world.  What is the Shiba Inu community working on right now? The Shiba Inu team launched a decentralized exchange called Shibaswap with 2 new tokens, LEASH and BONE. LEASH is a scarce supply token that is used to offer incentives on Shibaswap. BONE is the governance token for holders to vote on proposals on Doggy DAO.

Shiba Inu

Shiba Inu is trending with community members expressing mixed sentiments, from excitement about potential rallies to concerns about dilution and the project's long-term viability. Some traders are pointing to burn rates and potential ETF inclusions as bullish catalysts, while others suggest the meme coin's moment has passed amid a saturated altcoin market. Discussions also involve comparisons to other meme coins and broader market trends.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is trending amid discussions around the launch of spot ETFs and their potential impact on price, with some anticipating a supply shock and price surge. The community is debating whether XRP can decouple from Bitcoin's price movements, citing upcoming regulatory clarity and real-world utility as potential catalysts. Bearish sentiment remains, with some traders pointing to the token's historical performance and the influence of Ripple's holdings.

StarkNet is a permissionless decentralized Layer 2 (L2) validity rollup, built to allow Ethereum to scale via cryptographic protocols called STARKs, without compromising Ethereum’s core principles of decentralization, transparency, inclusivity and security. The StarkNet Token is needed to operate the ecosystem, maintain and secure it, decide on its values and strategic goals, and direct its evolution. This token will be required for (i) governance, (ii) payment of transaction fees on StarkNet, and (iii) participation in StarkNet’s consensus mechanism.

Strike Coin

Starknet (STRK) is trending as the community discusses its potential connection to Zcash ($ZEC) and its capabilities in scaling Bitcoin ($BTC) and Ethereum ($ETH) with zero-knowledge proofs. Some view Starknet as an undervalued play within the crypto space, drawing comparisons to previous surges and highlighting its growing ecosystem and solid team. The ticker confusion on Stocktwits is also a hot topic.

AKUMA INU was born in BASE, the underground arena that has come to be known amongst crypto degens as "The Origin Pit". Forged in the frenzied fires of market volatility, AKUMA INU has emerged as the ultimate embodiment of the degen spirit - wild, unyielding, and relentless in the pursuit of crypto supremacy. Akuma Inu is here on Base chain, and he is here to stay. Come join us on our amazing journey!

Akuma Inu

Akuma Inu is gaining attention as traders discuss its potential for significant gains, citing its current price being far from its all-time high. The community is actively speculating on a potential breakout, with some highlighting its micro cap status and recent price surge. Others are pointing to the potential for a return to previous highs.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is seeing increased volatility as the community debates recent price drops and potential support levels. Discussions range from identifying possible bottom prices to analyzing the impact of institutional buying and potential market manipulation. Some traders are weighing the possibility of a significant bearish trend, while others remain optimistic about a future rebound.

GraniteShares ETF Trust - GraniteShares 2x Long MARA Daily ETF

GraniteShares 2x Long MARA Daily ETF

MRAL is trending as traders discuss its leveraged exposure to MARA, a Bitcoin mining company, and anticipate potential upside from upcoming earnings and possible interest rate cuts. Community members are weighing the potential for a gamma squeeze and highlighting MARA's Bitcoin holdings, speculating on significant gains. Some traders are actively swapping MARA shares for MRAL, aiming to amplify potential profits.

Telcoin is a multi-national fintech company  integrating blockchain technology, telecommunications, and digital banking to revolutionize global finance. It aims to provide borderless, instant, and affordable financial services to mobile phone users worldwide. Telcoin offers the Telcoin Wallet, a multi-signature DeFi wallet supporting more than 100 digital assets and remittances to eWallets and bank accounts globally. Telcoin is regulated as a Virtual Asset Service Provider in the EU (Lithuania) and Argentina, a Major Payment Institution in Singapore, and a Money Services Business in the US, Canada, and Australia.   Telcoin is designed to complement telecom, mobile money, and e-wallet partners globally with both traditional fiat and blockchain transaction rails that underpin our fast and affordable digital financial service offerings. Telcoin combines the best parts of the burgeoning DeFi ecosystem with our compliance-focused approach to each market, ensuring that the company takes on a fraction of traditional financial counterparty, execution, and custody risks.  The Telcoin Association is a Swiss non-profit organization domiciled in Lugano, Switzerland and is governed by a decentralized group of Miner Councils that run the various aspects of the Telcoin Platform, including the management of the Telcoin (TEL) token. Read more about the Telcoin Association [here](https://www.telcoin.org).

Telcoin

Telcoin is trending as the community discusses its potential, especially given its regulatory progress and unique position as a digital asset bank; they are actively watching for exchange listings and the launch of its eUSD stablecoin. Some community members are speculating on potential partnerships and future price targets, highlighting the potential for significant growth and mainstream adoption. Despite some mixed sentiment regarding past performance, excitement is building around upcoming developments and the long-term vision.

Pimco Exchange Traded Fund - PIMCO 25+ Year Zero Coupon U.S. Treasury Index Exchange-Traded Fund

ZROZ is trending as bond yields fluctuate amid discussions around economic outlook and potential rate cuts, with some suggesting bonds offer a better risk-reward than equities currently. The community is weighing the potential for significant gains in long-term treasuries against inflationary risks and analyzing technical indicators for entry points. Investors are also comparing ZROZ to similar ETFs and considering its potential as a hedge.

Day One Biopharmaceuticals, Inc. operates as a holding company. The firm, through its subsidiary, develops and commercializes targeted therapies for patients of all ages with genetically defined cancers. Its products include DAY101 and pimsertib. The company was founded by Julie Grant and Samuel C. Blackman in November 2018 and is headquartered in Brisbane, CA.

Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals is trending amid discussions around a potential acquisition following news of the company acquiring Mersana Therapeutics. Community members are analyzing the strategic rationale and financial implications of the deal, particularly how it may expand Day One's oncology pipeline through innovative antibody-drug conjugate platforms. Some investors feel the management team burned funds picking up the wrong ticker at the wrong time instead of selling.

statis crypto Watchlist

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Sanjay Singh Sells 18,777 Shares of MannKind (NASDAQ:MNKD) Stock

MannKind Corporation (NASDAQ:MNKD - Get Free Report) EVP Sanjay Singh sold 18,777 shares of the company's stock in a transaction on Friday, November 14th. The shares were sold at an average price of...

MannKind (NASDAQ:MNKD) Now Covered by Leerink Partners

Leerink Partners initiated coverage on MannKind in a report on Thursday. They set an "outperform" rating and a $7.00 price target for the company...

Wedbush Forecasts MannKind's FY2025 Earnings (NASDAQ:MNKD)

MannKind Corporation (NASDAQ:MNKD - Free Report) - Equities research analysts at Wedbush increased their FY2025 EPS estimates for shares of MannKind in a research note issued on Monday, November...

Royal Bank Of Canada Has Lowered Expectations for MannKind (NASDAQ:MNKD) Stock Price

Royal Bank Of Canada decreased their price target on MannKind from $8.00 to $7.50 and set an "outperform" rating for the company in a research note on Tuesday...

MannKind (NASDAQ:MNKD) Price Target Lowered to $8.00 at Wells Fargo & Company

Wells Fargo & Company reduced their price objective on shares of MannKind from $10.00 to $8.00 and set an "overweight" rating on the stock in a research note on Tuesday...

Los Angeles Capital Management LLC Buys 177,440 Shares of MannKind Corporation $MNKD

Los Angeles Capital Management LLC lifted its position in MannKind Corporation (NASDAQ:MNKD - Free Report) by 68.3% during the second quarter, according to the company in its most recent Form 13F...

MannKind (NASDAQ:MNKD) Shares Gap Down - Here's What Happened

MannKind (NASDAQ:MNKD) Shares Gap Down - What's Next...

MannKind (NASDAQ:MNKD) Announces Quarterly Earnings Results

MannKind (NASDAQ:MNKD - Get Free Report) issued its quarterly earnings data on Wednesday. The biopharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, beating the consensus...

MannKind (NASDAQ:MNKD) Shares Gap Up After Better-Than-Expected Earnings

MannKind (NASDAQ:MNKD) Shares Gap Up Following Earnings Beat...

<ul class="summary-bullets"><li>MannKind’s stock has gained momentum amid optimism over its expanding diabetes portfolio and 2026 milestones.</li><li>CEO Michael Castagna said the FDA has accepted its Afrezza pediatric application, potentially making it the first new insulin for U.S. children in a century.</li><li>MannKind is reviving its BlueHale smart inhaler and expanding in the $5.6 billion pediatric diabetes management market, according to Grand View Research.</li></ul><p>MannKind shares are closing in on a breakout after a record quarter, with investors betting on its Afrezza pediatric approval — the first new insulin for U.S. children in a century — and the return of its connected inhaler platform, BlueHale.</p><h2 class="st-heading-2"><strong>Shares Rebound Toward Breakout Zone</strong></h2><p>Shares of MannKind have surged nearly 80% from their August low of $3.42, closing Wednesday at $6.06, within 6% of where they began the year, as investors focus on Afrezza’s next phase of growth and a series of 2026 milestones. The stock hit its highest levels in over 9 months on Wednesday and logged its best&nbsp;session in more than 2 months.&nbsp;</p><p>The company reported&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/mannkind-stock-soar-after-upbeat-quarterly-earnings/cL2qn70REGU">record third-quarter (Q3) revenue</a> of $82 million, led by a 23% year-over-year rise in Afrezza inhaled insulin sales. Adjusted earnings of $0.07 per share beat consensus estimates of $0.02, according to Fiscal AI data.</p><h2 class="st-heading-2"><strong>Afrezza’s Pediatric Push&nbsp;</strong></h2><p>MannKind said the FDA has accepted its supplemental application to expand Afrezza to children aged 4 to 17, with a decision expected by May 2026. On the company’s Q3 earnings call, CEO Michael Castagna described the filing as a potential milestone that could make Afrezza the first new insulin for U.S. pediatric patients in more than a century.</p><p>Insulin therapy dates to 1922, when a 14-year-old boy became the first patient successfully treated, transforming type 1 diabetes from a fatal illness into a manageable condition, according to a&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC8802620/">Nature Medicine study</a> archived by the U.S. National Library of Medicine.</p><p>The global pediatric diabetes management market, which includes devices, monitoring systems, and therapeutics for children and adolescents with diabetes, was valued at about $5.59 billion in 2024 and is projected to reach $13.11 billion by 2033, according to&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.grandviewresearch.com/industry-analysis/pediatric-diabetes-management-market-report">Grand View Research</a>.</p><p>To prepare for the pediatric opportunity, MannKind is expanding its field and medical liaison teams, focusing on top pediatric diabetes centers, including Joslin Diabetes Center in Boston and the Barbara Davis Center in Denver.</p><p>The company also plans to roll out an updated Afrezza dose-conversion label early next year. Castagna said the change will help new prescribers correctly dose patients from the start and address “lack of effect,” which is the most common early complaint.</p><h2 class="st-heading-2"><strong>BlueHale Smart Inhaler Revived</strong></h2><p>MannKind is also reviving its BlueHale smart inhaler, which is a connected device that tracks insulin doses and integrates with continuous glucose monitors (CGMs). The latest version will feature reminders, dosing analytics, and time-in-range tracking to help patients and caregivers manage insulin use. The company plans to test BlueHale in its upcoming Inhaled First pediatric study, which aims to establish Afrezza as a first-choice bolus insulin for newly diagnosed youth with Type 1 diabetes.</p><h2 class="st-heading-2"><strong>Cardiometabolic Expansion And Pipeline Progress</strong></h2><p>In addition to diabetes, MannKind said the acquisition of scPharmaceuticals has strengthened its cardiometabolic portfolio.</p><p>A major milestone this quarter was the submission of the sNDA for the Furoscix ReadyFlow auto-injector. Upon approval, the Furoscix ReadyFlow auto-injector will simplify admissions, increase treatment options, and lower the cost of goods, creating capital that can be reinvested for growth and margin improvement.</p><p>The company is also advancing bumetanid DPI (MNKD-701) into preclinical development. Castagna said the inhaled formulation could serve patients who prefer inhaling rather than injecting. MannKind’s Technosphere platform has previously demonstrated IV-like onset and sustained efficacy in programs for insulin, treprostinil, and migraine, which the company believes supports the viability of MNKD-701.</p><h2 class="st-heading-2"><strong>Afrezza Upgrade Spurs Optimism On Stocktwits</strong></h2><p>On Stocktwits, retail sentiment for MannKind was ‘extremely bullish’ amid a 360% surge in 24-hour message volume.</p><figure class="image"><img style="aspect-ratio:967/139;" src="https://news.stocktwits-cdn.com/mnkd_ss_jpg_0feeeb3429.webp" alt="mnkd ss.jpg" width="967" height="139"><figcaption>MNKD sentiment and message volume as of November 5 | Source: Stocktwits</figcaption></figure><p>One user highlighted that MannKind’s upcoming Afrezza label update and the introduction of 2-unit cartridges could make dosing easier, improve “time in range,” and ultimately demonstrate Afrezza’s superiority over traditional insulins in future studies.</p><p><stembedurl>https://stocktwits.com/jlonards/message/635113690</stembedurl></p><p>Another user described MannKind as a “deliberate, step-by-step growth story,” adding that they plan to increase their position in the stock next week.</p><p><stembedurl>https://stocktwits.com/TwitsNelson123/message/635111816</stembedurl></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Shares of MannKind (MNKD) have surged nearly 80% from their August low of $3.42. (Photo credit: Getty Images)

MannKind Stock Nears Breakout As FDA Reviews First New Insulin For Kids In A Century

MannKind’s stock has gained momentum amid optimism over its expanding diabetes portfolio and 2026 milestones.

Equity

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Danbury, CT.

Mannkind Corp

Will NVIDIA ($NVDA) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

) beat quarterly earnings? 
 
*Powered by Polymarket

MNKD
Mannkind Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest MNKD News

MNKDMannkind Corp